Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
about
The role of epithelial to mesenchymal transition in resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancerTherapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidenceSrc inhibitors act through different mechanisms in Non-Small Cell Lung Cancer models depending on EGFR and RAS mutational status.Efficacy of continuous EGFR-inhibition and role of Hedgehog in EGFR acquired resistance in human lung cancer cells with activating mutation of EGFRIntrinsic resistance to selumetinib, a selective inhibitor of MEK1/2, by cAMP-dependent protein kinase A activation in human lung and colorectal cancer cells.Follistatin is a novel biomarker for lung adenocarcinoma in humans.Metformin increases antitumor activity of MEK inhibitors through GLI1 downregulation in LKB1 positive human NSCLC cancer cells.Mechanisms of acquired resistance to targeted cancer therapies.Metformin in lung cancer: rationale for a combination therapy.Type III or allosteric kinase inhibitors for the treatment of non-small cell lung cancer.Tumor heterogeneity: evolution through space and time in EGFR mutant non small cell lung cancer patients.Activation of an AKT/FOXM1/STMN1 pathway drives resistance to tyrosine kinase inhibitors in lung cancer.Targeting the KRAS variant for treatment of non-small cell lung cancer: potential therapeutic applications.IGF1R depletion facilitates MET-amplification as mechanism of acquired resistance to erlotinib in HCC827 NSCLC cells.Targeting the MEK signaling pathway in non-small cell lung cancer (NSCLC) patients with RAS aberrations.Acquisition of EMT phenotype in the gefitinib-resistant cells of a head and neck squamous cell carcinoma cell line through Akt/GSK-3β/snail signalling pathway.Selumetinib: a promising pharmacologic approach for KRAS-mutant advanced non-small-cell lung cancer.Years of sorafenib investigation in advanced non-small cell lung cancer: is there a 'NExUS' linking an unsuccessful treatment and a potentially active one?Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation.Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells.The Challenges of Modeling Drug Resistance to Antiangiogenic Therapy.Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer.LXR ligands induce apoptosis of EGFR-TKI-resistant human lung cancer cells in vitro by inhibiting Akt-NF-κB activation.
P2860
Q26749110-A60EDC2D-54B7-4F15-AAEC-6C95A1A21981Q28071772-BFB7A627-0780-483F-9FFB-89A7EE793344Q30278774-AADD45E3-C3FC-4929-BA1E-DD5516414AACQ33618558-41E8BAFB-76D1-4EB8-8AF8-2798CB5DA9D4Q34273541-CE334254-C5F7-4FFD-AFA7-BA867687AF3EQ34408498-A56D1D49-8995-4C06-8B82-27DA96DE7749Q36782414-91D71373-C2A2-4469-8516-C1105CA40C66Q38034816-08502A28-1171-42E7-841B-54F2DEE7F84EQ38128357-BF8F359C-AF03-4837-BC51-316DDD7708FEQ38199737-4DD2DAEF-5D25-4D28-A30F-BEB1726AC368Q38390044-D08C5D15-0056-4F55-8F18-5F9A317897F6Q38603815-254DC6EE-4F51-4F86-9D9E-8994DA06311BQ38682370-4F019D5D-06D6-40A9-A336-A6A5F077EC16Q38707122-D13412A4-A540-4746-8D97-C0015488408FQ38740315-0C702BFF-A0B0-4D58-90F7-65D417D92313Q39399913-8B196C68-1B4D-43AD-8451-6DB329A81307Q39466460-15DEC202-3136-4201-9A20-D6804F2F6B8EQ41867909-15809D7C-3EE9-46C2-B870-DEAF4BD8B6D9Q42139529-204FB844-9A9F-42DA-9803-A6B4C367E28FQ42437883-CB98C325-CB28-4832-991A-DAD5C648C37DQ44456046-093B3FD4-7075-4483-B138-CBE62BB7DA1CQ51752412-285EE213-E169-4DC5-AF21-7EB322DC7231Q54979649-F850E093-7C9D-4355-824C-7307147A5F91
P2860
Antitumour efficacy of MEK inhibitors in human lung cancer cells and their derivatives with acquired resistance to different tyrosine kinase inhibitors
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@ast
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@en
type
label
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@ast
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@en
prefLabel
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@ast
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@en
P2093
P2860
P50
P356
P1476
Antitumour efficacy of MEK inh ...... ent tyrosine kinase inhibitors
@en
P2093
C Tuccillo
E Martinelli
J V Heymach
P2860
P2888
P304
P356
10.1038/BJC.2011.244
P407
P577
2011-07-12T00:00:00Z